BioSpace News Archive

Once-WeeklyTwirla is the first and only contraceptive patch that combines levonorgestrel and ethinyl estradiol (EE)

Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that it has been notified by the U.S. Food and Drug Administration (FDA) that a clinical hold has been placed on patient enrollment and dosing in an ongoing Phase 1/2 dose-escalation clinical trial evaluating BPX-601 in patients with previously treated metastatic pancreatic or prostate cancer.

Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced dosing of the first patient in its second U.S. pivotal Phase 3 clinical study (“Cardigan II study”) evaluating sofpironium bromide gel, 15% in approximately 350 subjects aged nine and older with primary axillary (underarm) hyperhidrosis

Preliminary duration of response of up to 168 days observed, with six of seven ongoing responses as of cut-off date

Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced interim data from the ongoing Phase 1/2 clinical trial of MB-106, a CD20-targeted, autologous CAR T cell therapy for patients with relapsed or refractory B-cell non-Hodgkin lymphoma (“NHL”

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that additional results from GALACTIC-HF (Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility in Heart Failure), the Phase 3 event-driven cardiovascular outcomes clinical trial of omecamtiv mecarbil, were presented by John Teerlink, M.D., Professor of Medicine,

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will hold a conference call on Wednesday, December 9, 2020 at 10:00 a.m. ET to discuss clinical data from ongoing studies evaluating eganelisib in triple negative breast cancer (TNBC) which will be presented during the San Antonio Breast Cancer Symposium (SABCS) being held virtually, December 8-11, 2020.

9 Meters Biopharma, Inc., a clinical-stage rare and unmet needs-focused gastroenterology company, announced positive topline results from its open-label Phase 1b/2a clinical trial evaluating NM-002, its proprietary long-acting glucagon-like peptide-1 receptor agonist in adults with short bowel syndrome.

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced its unaudited financial results for the third quarter ended September 30, 2020.

Catalyst Biosciences, Inc. (NASDAQ: CBIO) presented a poster today at the 62nd Annual American Society of Hematology (ASH) meeting, held virtually December 5-8, 2020, highlighting its Phase 3 Study, Crimson 1